<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45393">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125526</url>
  </required_header>
  <id_info>
    <org_study_id>IABPinPI</org_study_id>
    <secondary_id>STW-11052</secondary_id>
    <nct_id>NCT02125526</nct_id>
  </id_info>
  <brief_title>Intra-aortic Balloon Pump in Extensive Myocardial Infarction With Persistent Ischemia</brief_title>
  <official_title>Use of Intra-aortic Balloon Pump to Reduce Mortality in Extensive Myocardial Infarction With Persistent Ischemia; a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lokien van Nunen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting Toegepaste Wetenschappen (project number 11052)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maquet Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <authority>The Netherlands: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting with large myocardial infarction and signs of persistent ischemia after
      successful percutaneous coronary intervention, have a poor prognosis with respect to outcome
      and development of heart failure in the future.

      The hypothesis of this study is that in patients in whom persistent ischemia is present, use
      of intra-aortic balloon pump will be beneficial and improve outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In some patients presenting with large myocardial infarction and poor hemodynamic condition,
      intra-aortic balloon counterpulsation is effective in alleviating cardiogenic shock. In
      others, the use of intra-aortic balloon pump has no effect at all. The investigators believe
      this is dependent on the presence of persisting ischemia after successful epicardial
      reperfusion, known as no-reflow.

      In the presence of persisting ischemia, the investigators believe us of the intra-aortic
      balloon pump will relieve ischemia and improve outcome.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite endpoint of mortality, necessity for mechanical support due to hemodynamic deterioration, and hospital admission for heart failure</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Persisting Ischemia</condition>
  <condition>No Reflow</condition>
  <arm_group>
    <arm_group_label>IABP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After primary percutaneous coronary intervention, IABP will be implanted for 12-24 hours to alleviate persisting ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After primary percutaneous coronary intervention, this group undergoes standard treatment according to the guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intra-aortic balloon pump</intervention_name>
    <description>The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.</description>
    <arm_group_label>IABP group</arm_group_label>
    <other_name>IABP</other_name>
    <other_name>Intra-aortic balloon counterpulsation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ST-segment elevation myocardial infarction with summed ST-segment deviation â‰¥15
             mm.

          -  Insufficient ST-segment resolution (&lt;50%) on the ECG made 10-30 minutes after the
             primary PCI in the catheterization laboratory.

        Exclusion Criteria:

          -  Initial summed ST-segment deviation less than 15 mm

          -  ST-segment resolution &gt; 50% on the ECG performed in the catheterization laboratory

          -  Chest pain onset less than 2 or more than 8 hours before arrival

          -  Severe aortic valve stenosis/regurgitation

          -  Aortic abnormalities prohibitive for use of intra aortic balloon pump

          -  Full blown cardiogenic shock with immediate requirement of left ventricular assist
             device as judged necessary by the operator

          -  Inability to provide informed consent

          -  Pregnancy

          -  Inability to perform coronary angiography by the femoral approach
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nico H.J. Pijls, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Hospital Eindhoven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lokien X van Nunen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Hospital Eindhoven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nico H.J. Pijls, MD PhD</last_name>
    <phone>+31 40 2397004</phone>
    <email>carias@cze.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lokien X. van Nunen, MD</last_name>
    <phone>+31 40 2397004</phone>
    <email>lokien.v.nunen@cze.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lokien X van Nunen, MD</last_name>
      <phone>+31 40 2397004</phone>
      <email>lokien.v.nunen@cze.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid Aarts</last_name>
      <phone>+31 402397004</phone>
      <email>carias@cze.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Nico HJ Pijls, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lokien X van Nunen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van Nunen LX, van 't Veer M, Schampaert S, Steerneman BJ, Rutten MC, van de Vosse FN, Pijls NH. Intra-aortic balloon counterpulsation in acute myocardial infarction: old and emerging indications. Neth Heart J. 2013 Dec;21(12):554-60. doi: 10.1007/s12471-013-0485-9.</citation>
    <PMID>24170231</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Lokien van Nunen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Persisting ischemia</keyword>
  <keyword>No reflow</keyword>
  <keyword>Intra-aortic balloon pump</keyword>
  <keyword>Exhausted autoregulation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
